玻璃体内注射AAV2.COMP-Ang1可减轻老年糖尿病小鼠视网膜深层毛细血管丛扩张
研究在6月龄雄性Ins2Akita糖尿病小鼠玻璃体内注射AAV2.COMP-Ang1,观察其对视网膜血管和神经的影响。结果显示治疗可阻止深层微血管密度增加,但未改善视网膜变薄或视力下降。结论提示血管正常化不足以逆转神经退行性改变,需额外干预。
要点
- AAV2.COMP-Ang1可阻止糖尿病小鼠深层视网膜微血管密度增加。
- 治疗未改善视网膜变薄或糖尿病视网膜病变相关视力丧失。
- 血管正常化不能减轻神经视网膜退行性变,需针对神经退行性改变额外干预。
核心结论
- 糖尿病Ins2Akita小鼠深层视网膜微血管晚期出现紊乱性血管增殖。
- 玻璃体内注射AAV2.COMP-Ang1可阻断深层微血管密度增加,即使在首个可检测血管缺陷出现后给药。
- 改善血管正常化未减轻神经视网膜退行性变或视力丧失,需额外干预应对已发生的神经退行性改变。
研究设计与样本
- 研究将AAV2.COMP-Ang1双侧玻璃体内注射入6月龄雄性Ins2Akita小鼠。
- 年龄匹配对照包括未注射的C57BL/6J和Ins2Akita雄性小鼠,以及注射PBS或AAV2.REPORTER(AcGFP或LacZ)的Ins2Akita雄性小鼠。
- 在基线和10.5个月终点进行在体视网膜厚度和视力检测,离体测量视网膜铺片血管参数,并用Western blot检测蛋白表达。
主要发现
- 三个Ins2Akita对照组在10.5个月时深层血管密度较未注射C57BL/6J视网膜显著增加(以血管面积、长度、腔隙度和连接点数目衡量)。
- AAV2.COMP-Ang1治疗的Ins2Akita视网膜深层微血管密度在所有参数上更接近未注射C57BL/6J视网膜。
- 治疗的糖尿病视网膜未发现视网膜变薄或糖尿病视网膜病变相关视力丧失的显著改善。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: We determine whether intravitreal angiopoietin-1 combined with the short coiled-coil domain of cartilage oligomeric matrix protein by adeno-associated viral serotype 2 (AAV2.COMP-Ang1) delivery following the onset of vascular damage could rescue or repair damaged vascular beds and attenuate neuronal atrophy and dysfunction in the retinas of aged diabetic mice. METHODS: AAV2.COMP-Ang1 was bilaterally injected into the vitreous of 6-month-old male Ins2Akita mice. Age-matched controls consisted of uninjected C57BL/6J and Ins2Akita males, and of Ins2Akita males injected with PBS or AAV2.REPORTER (AcGFP or LacZ). Retinal thickness and visual acuity were measured in vivo at baseline and at the 10.5-month endpoint. Ex vivo vascular parameters were measured from retinal flat mounts, and Western blot was used to detect protein expression. RESULTS: All three Ins2Akita control groups showed significantly increased deep vascular density at 10.5 months compared to uninjected C57BL/6J retinas (as measured by vessel area, length, lacunarity, and number of junctions). In contrast, deep microvascular density of Ins2Akita retinas treated with AAV2.COMP-Ang1 was more similar to uninjected C57BL/6J retinas for all parameters. However, no significant improvement in retinal thinning or diabetic retinopathy-associated visual loss was found in treated diabetic retinas. CONCLUSIONS: Deep retinal microvasculature of diabetic Ins2Akita eyes shows late stage changes consistent with disorganized vascular proliferation. We show that intravitreally injected AAV2.COMP-Ang1 blocks this increase in deep microvascularity, even when administered subsequent to development of the first detectable vascular defects. However, improving vascular normalization did not attenuate neuroretinal degeneration or loss of visual acuity. Therefore, additional interventions are required to address neurodegenerative changes that are already underway.
引用
- Carroll LS, Uehara H, Fang D, et al. Intravitreal AAV2.COMP-Ang1 Attenuates Deep Capillary Plexus Expansion in the Aged Diabetic Mouse Retina. Invest Ophthalmol Vis Sci. 2019. PMID: 31185088. doi:10.1167/iovs.18-26182
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。